These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33424833)

  • 21. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
    Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination.
    Pakkanen SH; Kantele JM; Kantele A
    Vaccine; 2012 Sep; 30(42):6047-53. PubMed ID: 22858557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 28. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
    Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
    Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Khanam F; Babu G; Rahman N; Liu X; Rajib NH; Ahmed SU; Hossen MI; Biswas PK; Kelly S; Thesis-Nyland K; Mujadidi Y; McMillan NAJ; Pollard AJ; Clemens JD; Qadri F
    Vaccine; 2023 May; 41(19):3137-3140. PubMed ID: 37061369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A; Pakkanen SH; Siitonen A; Karttunen R; Kantele JM
    Vaccine; 2012 Nov; 30(50):7238-45. PubMed ID: 23084770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
    Tacket CO; Levine MM; Robbins JB
    Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-Associated Heterogeneity of Ty21a-Induced T Cell Responses to HLA-E Restricted
    Rudolph ME; McArthur MA; Magder LS; Barnes RS; Chen WH; Sztein MB
    Front Immunol; 2019; 10():257. PubMed ID: 30886613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans.
    Wahid R; Fresnay S; Levine MM; Sztein MB
    Mucosal Immunol; 2015 Nov; 8(6):1349-59. PubMed ID: 25872480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
    Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.